Imagen de Portada

Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Bhagwat Prasad
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Correction to “Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies”
Publicado: (2026)

Participants in the FDA's Biomarker Qualification Program
por: Mahnum Shahzad, et al.
Publicado: (2025)

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
por: Wei Gao, et al.
Publicado: (2025)

Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors
por: Jessie P. Bakker, et al.
Publicado: (2024)

Interchanging Biosimilars Using Proteomics
por: Piet H. van der Graaf, et al.
Publicado: (2025)

Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
por: Md Masud Parvez, et al.
Publicado: (2024)

Quantitative Approaches to Accelerate MASH Drug Discovery and Development
por: Yasmeen Abouelhassan, et al.
Publicado: (2025)

Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
por: Aarzoo Thakur, et al.
Publicado: (2024)

Home Is Where the Research Is: The Promise of Decentralized Clinical Trials
por: Sarah A. Holstein
Publicado: (2025)

Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease
por: Chanchala Kaddi, et al.
Publicado: (2024)

Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ‐1a Biologics to Inform Potential Utility in Biosimilar Development
por: Lakshmi Manasa S. Chekka, et al.
Publicado: (2025)

The Promise of Health for All: A Collaborative Model to Close Treatment Gaps for Neglected Diseases
por: Delali Attipoe
Publicado: (2024)

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov
por: Chunhui Huang, et al.
Publicado: (2024)

From Challenge to Opportunity: How Shwachman–Diamond Syndrome Became a Promising Target for Therapy Development
por: Eszter S. Hars, et al.
Publicado: (2024)

Methodology for Good Machine Learning with Multi‐Omics Data
por: Thibaud Coroller, et al.
Publicado: (2024)

Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
por: Yow‐Ming C. Wang, et al.
Publicado: (2024)

The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities
por: Matthew M. Abernathy, et al.
Publicado: (2024)

Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development
por: Georgi I. Kapitanov, et al.
Publicado: (2025)

Quantitative Lesion‐Level Modeling Reveals Organ‐Dependent Therapeutic Response
por: Ian Dilley, et al.
Publicado: (2026)

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology
por: Mohamed Elmeliegy, et al.
Publicado: (2024)

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis
por: Milou A. Hogervorst, et al.
Publicado: (2025)

Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare Diseases
por: Susana Neves‐Zaph, et al.
Publicado: (2024)

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs
por: Darshak Gadara, et al.
Publicado: (2026)

Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity
por: Alan Shi, et al.
Publicado: (2025)

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation
por: Wangda Zhou, et al.
Publicado: (2025)

Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency
por: Cynthia Huber, et al.
Publicado: (2025)

Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
por: Xiaozhi Liao, et al.
Publicado: (2024)

In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect‐Compartment Model—Commentary on Sheiner et al.
por: Mats O. Karlsson
Publicado: (2025)

Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making
por: Linh M. Van, et al.
Publicado: (2025)

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide
por: Emmanuel Chigutsa, et al.
Publicado: (2025)

Emulating Comparative Oncology Trials With Real‐World Evidence Studies ( ENCORE ): Process Development and Methodological Considerations for Oncology Real‐World Data
por: Janick Weberpals, et al.
Publicado: (2026)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2025)

ASCPT News
Publicado: (2024)